A Phase 2 interventional study of Adrenocorticotropic Hormone Gel in Dermatomyositis and Polymyositis, sponsored by Rohit Aggarwal, MD. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-01.
Sponsored by Rohit Aggarwal, MD · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Dermatomyositis with a site in United States — 29 open to participants now, 33 under way, 6 of them phase 3. Dermatomyositis · United States.
Among the 94 studies in Dermatomyositis with a site in United States, this one is the 55th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2013, is one of 31 in phase 2, and was the 28th registered.
184 studies on the registry are indexed under Dermatomyositis; 62 are open to participants now.
Browse Dermatomyositis studies →29 of the 94 studies in Dermatomyositis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 18–62
Fate Therapeutics · Sites in United States
Ages 18–70
University of Miami · Sites in United States
Ages 18+
Cartesian Therapeutics · Sites in United States
Ages 12+
Restem, LLC. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Dermatomyositis studies recruiting now, 24 (49%) set no upper age limit and 15 (31%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 42 · Phase 3 17 · Phase 4 2
First in 1990; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 35 across 130 interventional studies indexed under Dermatomyositis.
Median enrollment 25 across the 73 interventional studies, 540 across the 18 observational. Of the 55 that completed or were terminated, 26 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 94 have an industry lead sponsor. The 10 most frequent:
Rohit Aggarwal, MD is the lead sponsor of 3 studies on the registry; none are open to participants now.
Rohit Aggarwal, MD has 1 study filed under Dermatomyositis — fewer than ten, so there is no comparison to draw.
5 of the studies in Dermatomyositis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06284954argenxA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | 2026-11 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT06298019Stanford UniversityStudy of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis | 2027-06 |
| NCT07486869University of MiamiEmapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 94 studies in Dermatomyositis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to evaluate the effectiveness of the study drug, ACTH Gel in people diagnosed with dermatomyositis a disease that causes muscle weakness and is associated with a rash (DM) or polymyositis (PM) a disease that causes muscle weakness without a rash. The study doctors want to evaluate whether ACTH Gel will improve the symptoms of this disease. This drug is approved by the Food and Drug Administration (FDA) for dermatomyositis (DM) and polymyositis (PM). ACTH gel has been an FDA-approved treatment for myositis since 1952, and in 2010 the FDA retained PM and DM as diseases approved for ACTH gel use.
Despite its FDA approval there is very limited data on its clinical effectiveness in PM and DM. There was a recent study published in the peer-review journal Drug Design, Development and Therapy on a retrospective case series evaluating Acthar in the treatment of PM and DM. Acthar was administered to five patients who had previously failed multiple steroid and immunosuppressant treatment regimens. The patients received injections of Acthar over the course of 12 weeks or more. Improvement in PM and DM symptoms related to disease exacerbations was seen in all five patients. Symptom improvements included increased muscle strength, resolution of disease-related skin manifestations and improvements in the ability to perform tasks associated with daily living. All of these patients tolerated the treatment well with no significant side effects reported. The paper, "Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series," was authored by Dr. Todd Levine, M.D., Co-Director of the Neurophysiology Department at Banner Good Samaritan Medical Center, Assistant Professor at the University of Arizona in Neurology, and Member of Phoenix Neurological Associates.
H.P. Acthar® Gel, or Acthar, is a prescription medication containing the hormone adrenocorticotropin (hormone produced and secreted by the anterior pituitary gland), also known as ACTH. H.P. Acthar Gel is a highly purified preparation of adrenocorticotropic hormone (ACTH) in a gel that is designed to provide extended release of the ACTH following injection. Acthar was originally approved by the FDA in 1952. It is approved for use in 19 different conditions including dermatomyositis and polymyositis.
Acthar is designed to provide a prolonged release of the medication after it is injected. Acthar is not a steroid; it works by helping your body produce its own natural steroid hormones, such as cortisol, corticosterone, and aldosterone. Acthar is an injection that is given intramuscularly (into the muscle). Subjects enrolled in the study will be asked to self administer Acthar two times per week. Subjects will be provided training by the principal investigator on how to perform the self injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Active myositis as defined by baseline Manual Muscle Testing (MMT-8) no greater than 125/150 and at least 2 additional CSM meeting the criteria stipulated below:
To ensure that we can enroll active DM patients with a severe rash who may not meet the MMT-8 criterion noted above, we propose additional enrollment criteria such that the International Myositis Assessment and Clinical Studies (IMACS) definition of improvement (DOI) can potentially be met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acthar Gel (Adrenocorticotropic Hormone Gel)in refractory PM and DM patients using an open label design for 6 months. We will enroll 10 active and refractory PM/DM patients over a 15 month period, followed by 6 months of additional follow-up for each subject. Study subjects will self-administer subcutaneously H.P. Acthar Gel 80 units (1 ml) twice a week for a period of six months. Outcome measures were not evaluated on subjects who did not reach the 8 week time point in the trial.
Drug: Adrenocorticotropic Hormone Gel
H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
Also known as: H.P. Acthar Gel
Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI).
3 of any of the 6 core set measures (CSM) improved by ≥ 20%, with no more than 2 CSM worsening by ≥25% (worsening measure cannot include the MMT). The DOI should be met at least once on any of the 6 follow up visits and maintained until week 24. Subjects not meeting DOI during the trial are treatment failures.
Time frame: Primary end point: IMACS preliminary definition of improvement (DOI)
Steroid-sparing Effect of H.P. Acthar Gel in Refractory Adult PM and DM Patients.
Mean change in glucocorticoid dose (equivalent prednisone dose) at 24 weeks compared to baseline.
Time frame: Steroid sparing effect and safety and tolerability at 24 weeks compared to baseline
Subjects with active and refractory polymyositis or dermatomyositis were recruited at two clinical centers, The University of Pittsburgh and North Shore Long Island Jewish Center over a 16 month recruitment period. Two subjects did not reach the week 8 time point prior to withdrawing from the trial therefore additional subjects were enrolled.
| Milestone | Acthar Gel |
|---|---|
| Started | 12 |
| Visit 7: treatment phase completed | 10 |
| Visit 10: follow up phase completed | 8 |
| Completed | 10 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 2 |
3 of any of the 6 core set measures (CSM) improved by ≥ 20%, with no more than 2 CSM worsening by ≥25% (worsening measure cannot include the MMT). The DOI should be met at least once on any of the 6 follow up visits and maintained until week 24. Subjects not meeting DOI during the trial are treatment failures.
| Participants | Acthar Gel |
|---|---|
| Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI). | 7 |
Mean change in glucocorticoid dose (equivalent prednisone dose) at 24 weeks compared to baseline.
| mg | Acthar Gel |
|---|---|
| Follow Up 24 weeks | 2.3 ± 3.2 |
| Baseline | 18.5 ± 15.7 |
Collected over Adverse events were collected during the overall duration of the study (12 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acthar Gel | — | 3/10 (30%) | 7/10 (70%) |
| Event | Acthar Gel |
|---|---|
| Local infection with moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, aInfections and infestations | 2/10 |
| Avascular NecrosisMusculoskeletal and connective tissue disorders | 1/10 |
| Atrioventricular BlockCardiac disorders | 1/10 |
| Non-cardiac chest painGeneral disorders | 1/10 |
| Event | Acthar Gel |
|---|---|
| General disorders and administration site conditionsGeneral disorders | 4/10 |
| HyperglycemiaMetabolism and nutrition disorders | 3/10 |
| InsomniaPsychiatric disorders | 2/10 |
| CalcinosisSkin and subcutaneous tissue disorders | 2/10 |
| HypertensionVascular disorders | 2/10 |
| Sinus TachycardiaCardiac disorders | 1/10 |
| DiarrheaGastrointestinal disorders | 1/10 |
| SinusitisInfections and infestations | 1/10 |
| Upper Respiratory InfectionsInfections and infestations | 1/10 |
| Cholesterol highMetabolism and nutrition disorders | 1/10 |
A total of 12 participants were enrolled however only 11 participants were assessed for baseline characteristics due to one subject withdrawing after screening and never received study drug.
| Age, Categorical(Participants) | Acthar Gel |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 10 |
| >=65 years | 1 |
| Sex: Female, Male(Participants) | Acthar Gel |
|---|---|
| Female | 10 |
| Male | 1 |
| Ethnicity (NIH/OMB)(Participants) | Acthar Gel |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Acthar Gel |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Acthar Gel |
|---|---|
| United States | 11 |
| Diagnosis(Participants) | Acthar Gel |
|---|---|
| Dermatomyositis | 6 |
| Polymyositis | 5 |
| Disease Duration(years) | Acthar Gel |
|---|---|
| Mean | 2.0 ± 2.0 |
| Autoantibody Status(Participants) | Acthar Gel |
|---|---|
| Count of participants | 8 |
Plan to share: No
The record gives a start of Sep 2013, a primary completion of Sep 2015 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adrenocorticotropic Hormone
Rohit Aggarwal, MD